Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

[1] Borgstrom F(2007)The societal burden of osteoporosis in Sweden Bone 40 1602-1609

[2] Sobocki P(2007)Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465-475

[3] Strom O(1997)Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation J Bone Miner Res 12 24-35

[4] Burge R(2015)The future of life expectancy and life expectancy inequalities in England and Wales: Bayesian spatiotemporal forecasting Lancet 386 163-170

[5] Dawson-Hughes B(2017)Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble Lancet 389 1323-1335

[6] Solomon DH(2017)Osteoporosis treatment: recent developments and ongoing challenges Lancet Diabetes Endocrinol 5 898-907

[7] Wong JB(2016)Clinical practice. Postmenopausal osteoporosis N Engl J Med 374 254-262

[8] King A(2012)Benefits and risks of bisphosphonate therapy for osteoporosis J Clin Endocrinol Metab 97 2272-2282

[9] Tosteson A(2014)Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate Osteoporos Int 25 1953-1961

[10] Ray NF(2009)Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women Calcif Tissue Int 85 389-397

[1] Borgstrom F(2007)The societal burden of osteoporosis in Sweden Bone 40 1602-1609

[2] Sobocki P(2007)Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465-475

[3] Strom O(1997)Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation J Bone Miner Res 12 24-35

[4] Burge R(2015)The future of life expectancy and life expectancy inequalities in England and Wales: Bayesian spatiotemporal forecasting Lancet 386 163-170

[5] Dawson-Hughes B(2017)Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble Lancet 389 1323-1335

[6] Solomon DH(2017)Osteoporosis treatment: recent developments and ongoing challenges Lancet Diabetes Endocrinol 5 898-907

[7] Wong JB(2016)Clinical practice. Postmenopausal osteoporosis N Engl J Med 374 254-262

[8] King A(2012)Benefits and risks of bisphosphonate therapy for osteoporosis J Clin Endocrinol Metab 97 2272-2282

[9] Tosteson A(2014)Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate Osteoporos Int 25 1953-1961

[10] Ray NF(2009)Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women Calcif Tissue Int 85 389-397